Literature DB >> 23665726

Nasal nitric oxide is a marker of poor asthma control.

Enrico Heffler1, Stefano Pizzimenti, Iuliana Badiu, Giuseppe Guida, Fabio Luigi Massimo Ricciardolo, Caterina Bucca, Giovanni Rolla.   

Abstract

Asthma control, evaluated by symptoms, exacerbations rate and lung function may be greatly influenced by comorbidities, particularly chronic rhinosinusitis (CRS). Measurement of nasal nitric oxide (nNO) is a simple way to assess the severity of CRS. We aimed to analyze the relationship between asthma control and nasal NO. All patients with moderate-to-severe asthma on regular follow-up at our Outpatients' Clinic between November 2009 and April 2010 were included into the study. All patients were evaluated for asthma control by asthma control questionnaire (ACQ) and comorbidities (rhinitis, chronic rhinosinusitis with (CRSwNP) or without nasal polyps, obesity). Exhaled nitric oxide and nNO were obtained in all patients. Eighty-two patients were enrolled (mean age: 48 years, range: 21-80; 42 females). According to ACQ, 53 patients (64.6%) reported controlled asthma. Patients with uncontrolled asthma had lower nNO and higher prevalence of CRSwNP, with a significant correlation between nNO and ACQ. nNO is a biomarker negatively related to asthma control. As low nNO values were associated to CRSwNP, our results indicate that asthma control is highly influenced by this comorbidity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665726     DOI: 10.1088/1752-7155/7/2/026009

Source DB:  PubMed          Journal:  J Breath Res        ISSN: 1752-7155            Impact factor:   3.262


  7 in total

1.  Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties.

Authors:  Anton Amann; Pawel Mochalski; Vera Ruzsanyi; Yoav Y Broza; Hossam Haick
Journal:  J Breath Res       Date:  2014-02-24       Impact factor: 3.262

2.  Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.

Authors:  Enrico Heffler; Fabiana Saccheri; Marta Bartezaghi; Giorgio Walter Canonica
Journal:  Clin Transl Allergy       Date:  2020-06-26       Impact factor: 5.871

3.  Nasal nitric oxide is a useful biomarker for acute unilateral maxillary sinusitis in pediatric allergic rhinitis: A prospective observational cohort study.

Authors:  Yung-Sung Wen; Ching-Yuang Lin; Kuender D Yang; Chih-Hsing Hung; Yu-Jun Chang; Yi-Giien Tsai
Journal:  World Allergy Organ J       Date:  2019-05-17       Impact factor: 4.084

4.  Application of nitric oxide measurements in clinical conditions beyond asthma.

Authors:  Andrei Malinovschi; Dora Ludviksdottir; Ellen Tufvesson; Giovanni Rolla; Leif Bjermer; Kjell Alving; Zuzana Diamant
Journal:  Eur Clin Respir J       Date:  2015-08-17

Review 5.  Nasal Nitric Oxide in Chronic Rhinosinusitis with or without Nasal Polyps: A Systematic Review with Meta-Analysis.

Authors:  Pasquale Ambrosino; Antonio Molino; Giorgio Alfredo Spedicato; Paolo Parrella; Roberto Formisano; Andrea Motta; Matteo Nicola Dario Di Minno; Mauro Maniscalco
Journal:  J Clin Med       Date:  2020-01-11       Impact factor: 4.241

6.  Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).

Authors:  Enrico Heffler; Giovanna Elisiana Carpagnano; Elisabetta Favero; Giuseppe Guida; Mauro Maniscalco; Andrea Motta; Giovanni Paoletti; Giovanni Rolla; Eugenio Baraldi; Vincenza Pezzella; Giorgio Piacentini; Stefano Nardini
Journal:  Multidiscip Respir Med       Date:  2020-02-19

Review 7.  The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma.

Authors:  Giancarlo Marone; Francescopaolo Granata; Valentina Pucino; Antonio Pecoraro; Enrico Heffler; Stefania Loffredo; Guy W Scadding; Gilda Varricchi
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.